布地奈德福莫特罗与噻托溴铵联合治疗重度COPD稳定期患者的疗效观察  

Therapeutic effect of budesonide formoterol combined with tiotropium bromide in severe COPD patients in stable period

作　　者：孙红艳 肖桂贤[1] SUN Hongyan;XIAO Guixian(Department of Respiratory Medicine, Huanggu Branch Courts, the Second Affiliated Hospital of Shenyang Medical College, Shenyang 110035, China)

机构地区：[1]沈阳医学院附属第二医院皇姑院区呼吸科

出　　处：《中国现代医生》2019年第19期118-121,共4页China Modern Doctor

摘　　要：目的探讨布地奈德福莫特罗与噻托溴铵联合治疗重度COPD稳定期患者的疗效.方法收集2016年6月~2019年1月期间我院收治的重度COPD稳定期患者106例作为研究对象,随机分为两组,每组53例,对照组给予布地奈德福莫特罗粉剂治疗,研究组在对照组的基础上加用噻托溴铵治疗,两组均治疗6个月.比较两组6MWT,呼吸困难评分、肺功能、血气分析指标.结果治疗后两组6MWT较治疗前明显提高,而呼吸困难评分明显降低,差异有统计学意义(P<0.05);研究组6MWT高于对照组,呼吸困难评分低于对照组,两组差异有统计学意义(P<0.05).治疗后两组肺功能较治疗前明显提高,差异有统计学意义(P<0.05);研究组FVC、FEV1、FEV1/FVC高于对照组,两组差异有统计学意义(P<0.05).治疗后两组PaO2较治疗前明显提高,而PaCO2明显降低,差异有统计学意义(P<0.05);研究组PaO2高于对照组,PaCO2低于对照组,两组差异有统计学意义(P<0.05).结论布地奈德福莫特罗与噻托溴铵联合治疗重度COPD稳定期患者的疗效显著,能有效缓解患者的临床症状,提高肺功能,改善血气分析指标,效果优于单独应用布地奈德福莫特罗治疗.Objective To investigate the efficacy of budesonide fomodrol combined with tiotropium bromide in the treatment of severe COPD patients in stable period. Methods A total of severe COPD patients in stable period who were admitted in our hospital from June 2016 to January 2019 were enrolled in the study. They were randomly divided into two groups, with 53 patients in each group. The control group was treated with budesonide fomodrol powder. The study group was treated with tiotropium bromide based on the treatment of the control group, and both groups were treated for 6 months. The 6MWT, dyspnea score, lung function, and blood gas analysis indicators between the two groups were compared. Results After treatment, the 6MWT of the two groups was significantly improved compared with that before treatment, and the dyspnea score was significantly lower(P<0.05). The 6MWT of the study group was higher than that of the control group, and the dyspnea score was lower than that of the control group, the difference between two groups was statistically significant(P<0.05). After treatment, the lung function of the two groups was significantly higher than that before treatment(P<0.05). The FVC, FEV1 and FEV1/FVC of the study group were higher than those of the control group, and the difference was statistically significant(P<0.05). After treatment, the PaO2 level in the two groups was significantly higher than that before treatment, while the PaCO2 level was significantly lower(P<0.05). The PaO2 in the study group was higher than that in the control group, and the PaCO2 was lower than that of the control group. The difference between the two groups was statistically significant(P<0.05). Conclusion Budesonide formoterol combined with tiotropium bromide is effective in the treatment of severe COPD patients in stable period. It can effectively alleviate clinical symptoms, improve lung function and improve blood gas analysis index. The effect of the combined drugs is better than that of budefordide alone.

关 键 词：重度COPD稳定期 布地奈德福莫特罗 噻托溴铵 肺功能 

分 类 号：R563.9[医药卫生—呼吸系统]